Replies to post #64542 on Biotech Values

[DewDiligence]

>Roche nicely shopping on US Dollar weakness it seems good timing on their part<

The Arius deal is in Canadian dollars; the salient point is that the Swiss franc (Roche’s native currency) is unusually strong right now.


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

[masterlongevity]

I think Roche is making a bad move with DNA. DNA has been roche's heavily expanding cash cow for years.

IMHO, having worked there and knowing many of the mid to top brass, I think there will be a huge exodus of highly talented employees.

Genentech employees have always prided themsleves on not being "big Pharma" AKA beauracrtic, inflexible, too focused on bottom line, short term strategies and me too drugs. (whether this is warranted or not is up for debate. i felt they were going there 5 yrs ago when i left.)

A lot of employess ahve left over the past 2 years as the company has grown. I think the majority of employees who have been there for 2 yr or less will stay, but long termer will most likely leave. THis is particularly true of the scientists and R & D group. Commercial employees seem to care more about the salary and benefits, but the change culture and idea of working for big corporate pharma will scare away a lot of scientists. I predict a slew of new startups in the bay area.